source
- Novartis shares tumble as three late-stage drug candidates fail trialsNovartis' stock fell more than 13% this week after news that three of its late-stage programs did not meet expectations, pulling down other pharma stocks in the market. The antibody‑oligonucleotid…
- Sandoz to invest $1 billion in European biosimilar hub, targeting 100 biosimilars by 2040Sandoz announced at its investor day that it will spend roughly $1 billion to build a fully integrated European biosimilar hub as part of a plan to bring more than 100 biosimilars to market by 2040…